Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.40 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 8/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20930969 | 1.00 | MGLL (0.40) | MGLLFAAHGGPS1ALOX5KMT2A | |
| SCHEMBL19704405 | 1.00 | MGLL (0.40) | MGLLFAAHGGPS1ALOX5KMT2A | |
| SCHEMBL20616617 | 0.98 | MGLL (0.38) | MGLLFAAHGGPS1ALOX5KMT2A | |
| SCHEMBL21577922 | 0.96 | MGLL (0.38) | MGLLFAAHGGPS1ALOX5KMT2A | |
| SCHEMBL21158545 | 0.93 | MGLL (0.38) | MGLLFAAHGGPS1ALOX5KMT2A | |
| SCHEMBL21577840 | 0.91 | FAAH (0.36) | MGLLFAAHALOX5KMT2ASMN1; SMN2 | |
| SCHEMBL10316631 | 0.87 | TSHR (0.47) | MGLLFAAHCYP1A2ALDH1A1 | |
| SCHEMBL24916383 | 0.85 | MGLL (0.40) | MGLLFAAHGGPS1ALOX5KMT2A | |
| SCHEMBL20616631 | 0.82 | MGLL (0.38) | MGLLFAAHGGPS1ALOX5KMT2A | |
| SCHEMBL24916460 | 0.79 | CCR2 (0.34) | MGLLFAAHGGPS1ALOX5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139522-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-20190185507-A1 | Sofosbuvir Derivatives for the Treatment of Hepatitis C | SANDOZ AG (CH) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185507-A1 | Sofosbuvir Derivatives for the Treatment of Hepatitis C | HAVCR2, ZC3HAV1, GTF3C4 | MGLL 2205/4885FAAH 1622/4885GGPS1 1124/4885 |
| US-20210139522-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CFTR, ABCB11, CEL | MGLL 200/4885FAAH 4117/4885GGPS1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.